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At present, histopathological sub-classification of non-small cell lung cancer (NSCLC)does not seem to provide significant enough prognostic discrimination to influence
treatment decisions. However, recent evidence indicates that molecular aberrations or
gene profiling alone could be strong independent predictors of clinical outcome among
patients with NSCLC.1,2 Accumulating data suggest that the treatment of patients with
advanced NSCLC with the anti-epidermal growth factor receptor (EGFR) drugs may be
best guided by molecular analysis on the tumor samples.3,4 Candidate biomarkers that are
predictive of response and/or survival benefits include EGFR immunohistochemistry,
EGFR tyrosine kinase domain mutations, EGFR copy number assayed by fluorescent in
situ hybridization, and KRAS mutations. Current assays for these markers require the
availability of tumor tissue samples, yet two thirds of patients with NSCLC present at
advanced stage. For these patients, diagnosis requires only minimal amounts of tumor
tissue or cells obtainable either bronchoscopically or by fine needle biopsy or aspiration.
Thus, diagnostic samples for supplementary molecular analyses (particularly mutations)
are often unavailable for these patients. Furthermore, formalin fixation may also reduce
the efficiency of polymerase chain reaction (PCR) or introduce artifactual “mutations” that
require independent repeat assays to exclude. Therefore, sample availability could repre-
sent a significant barrier to mandate molecular analyses for treatment decisions in all
patients. In fact, phase III erlotinib and gefitinib trials reported that molecular data from
analyses of archival pathology samples could be obtained in only 20% to 30% of
patients.5–7
In this issue of the journal, Lim et al.8 explored, within the usual hospital constraints,
the practicalities of incorporating mutational analysis for every newly diagnosed case of
NSCLC. They questioned whether, during a routine diagnostic biopsy procedure, the
acquisition of additional and separate “low-volume” samples that were processed directly
for DNA isolation, bypassing formalin fixation and paraffin embedding (FFPE), would
provide sufficient material for mutational analyses of three cancer-relevant genes, EGFR
(exons 18–21), p53 (exons 4–9), and KRAS (exon 2). The results of such molecular
analyses on low-volume biopsies from 33 patients were compared with similarly pro-
cessed tumor tissues obtained from 35 patients with surgically resected early-stage
NSCLC. They reported that the protocol was successful and was associated with no
significant morbidity, as self-resolving pneumothoraces occurred in only 15% of patients.
More importantly, the samples obtained were able to yield 67 to 6900 ng (median 812 ng)
DNA. The lowest yields from needle aspirates were 67 to 76 ng, yet these were still
sufficient to conduct at least nine PCR reactions. The success rates of obtaining sequenc-
ing data from these low-volume samples were 85% for each of the genes studied. Lim et
al. concluded that acquiring a separate low-volume lung biopsy for direct mutational
analysis from patients with lung cancer during their diagnostic procedures is feasible and
may be a valuable complement to future routine diagnostic workflow.
This study posed two separate questions. First, is it feasible for a routine diagnostic
biopsy procedure to obtain additional (non–formalin-fixed) samples for molecular anal-
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ysis? The answer is an unequivocal “Yes,” as the morbidity
was acceptably low, whereas DNA yields were adequate to
conduct several independent PCR studies. Second, and more
importantly, are mutational results from samples without
histological confirmation sufficiently reliable for making
treatment decisions? The authors argued that it is reasonable
to regard split (two) samples obtained from a single biopsy
procedure as being equivalent. Therefore, if the pathological
diagnosis on the FFPE specimen is cancer, one could assume
that the corresponding low-volume samples directly pro-
cessed for molecular analysis would contain sufficient tumor
cells to provide reliable mutational results. To test this hy-
pothesis, they compared the results of mutation analyses on
low volume samples with those of similarly acquired and
non-histologically verified samples from surgically resected
tumors. Surprisingly, the mutation profiles of these two
groups of samples were vastly different. Although the surgi-
cal specimens yields were slightly lower (26%) than previ-
ously reported rates of EGFR mutation in East-Asian pa-
tients,9 the characteristics of patients with mutations were
very typical, with mutation rates being higher among women,
never-smokers, and patients with adenocarcinoma. In con-
trast, although the low-volume samples yielded a comparable
EGFR mutation rate (25%), the patient characteristics were
highly unusual, with mutations found mainly among men,
ever-smokers, and patients with non-adenocarcinomas. Fur-
thermore, five of six patients with EGFR mutations had
identical double mutations on exon 21 (L858RL833V),
whereas the sixth patient had only the L833V mutation. The
high rate of the unusual double mutation almost certainly
indicates a PCR contamination problem, as L833V has been
reported very rarely. Notwithstanding the reliability issue of
these results, this study has not been appropriately designed
to answer the key question of whether histology-bypassed
biopsy samples provide results equivalent to analyses per-
formed on FFPE samples that were processed primarily for
histologic diagnosis. Such a question could only be answered
if parallel analyses were performed on the split FFPE and
histology-bypassed samples. The results of similar analyses
on resected specimens could provide additional evidence
concerning the necessity of histology in guiding the molec-
ular analysis of tissue.
Why then is bypassing histologic analysis of these split
low-volume samples potentially dangerous, especially when
the results are not correlated to the sample characteristics of
the diagnostic histology/cytology specimens? The main rea-
son is because NSCLC diagnoses in histo- and cytopathology
do not require the presence of a large number of diagnostic
malignant cells. However, tumor tissue is composed of inti-
mately mixed cancer and non-neoplastic host cells. An indi-
vidual tumor is variable in tumor cellularity overall, as well
as heterogeneity in the distribution of tumor and stromal
elements. Mutated DNA sequences that occur only in tumor
cell DNA can be overwhelmingly masked and becomes
unapparent (false negative) by sequencing when tumor cells
percentage is low (less than 30–40%). Detection of mutated
sequences is also dependent on the sensitivity of the tech-
nique. It is generally recognized that PCR-direct sequencing
may not be the most sensitive technique to detect mutations
when contamination by normal host DNA is significant.10
Although positive results that have been confirmed by repeat
analysis are reliable, negative results from a histology-by-
passed sample would require at least a correlation with the
histology of the corresponding diagnostic specimen to ensure
that a high percentage of tumor cells are present in the biopsy,
or to conduct a confirmatory molecular re-analysis of the
diagnostic FFPE specimen. Therefore, although there is merit
in securing additional biopsy samples for direct DNA isola-
tion and mutational analysis, interpretation of the results
should always be rendered in the context of histopathologic
and cytologic findings in the biopsy. This will reduce the
number of false negatives that may result in appropriate
patients being denied a highly effective anti-EGFR therapy.
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